Monthly
US$200
Billed every month
Sign in to subscribeAlfacalcidol Soft Capsules
As of 13 November 2026, for Alfacalcidol Soft Capsules, 9 applications are listed as under review at China's CDE; 3 companies have filed new generic applications in 2026; the chemical-drug catalogue lists 12 holders.
Companies, stages and changes, with each record available on this page.
Last 90 days: Accepted: 3 applications
Current coverage may be incomplete
Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.
Catalogue holders12View records ↓
Under-review filings9View records ↓
This year’s generic filers3View records ↓
NHSA approval numbers24View records ↓
API companies with A status9View records ↓
Chemical-drug catalogue
Loaded records: 12 holders; 4 in the quality-and-efficacy consistency-evaluation category, and 6 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| Nanjing Hai Jing Pharma Co., Ltd. romanized | Nanjing Hai Jing Pharma Co., Ltd. romanized | 国药准字H20264557 | 2026/05/27 | 0.5μg | Generic approved under the new chemical-drug registration classification | CDE |
| Nanjing Hai Jing Pharma Co., Ltd. romanized | Nanjing Hai Jing Pharma Co., Ltd. romanized | 国药准字H20264556 | 2026/05/27 | 1μg | Generic approved under the new chemical-drug registration classification | CDE |
| Nanjing Hai Jing Pharma Co., Ltd. romanized | Nanjing Hai Jing Pharma Co., Ltd. romanized | 国药准字H20264558 | 2026/05/27 | 0.25μg | Generic approved under the new chemical-drug registration classification | CDE |
| Nan Tong Hua Shan Pharma Co., Ltd. romanized | Nan Tong Hua Shan Pharma Co., Ltd. romanized | 国药准字H20000065 | 2026/05/25 | 0.25μg | Drug that passed quality-and-efficacy consistency evaluation | CDE |
| Hunan Yin Ze Hua Hao Bio Technology Co., Ltd. romanized | Nan Tong Hua Shan Pharma Co., Ltd. romanized | 国药准字H20264157 | 2026/04/29 | 0.5μg | Generic approved under the new chemical-drug registration classification | CDE |
| Hunan Yin Ze Hua Hao Bio Technology Co., Ltd. romanized | Nan Tong Hua Shan Pharma Co., Ltd. romanized | 国药准字H20264156 | 2026/04/29 | 0.25μg | Generic approved under the new chemical-drug registration classification | CDE |
| Ren Fu Pu Ke Pharma (Wuhan) Co., Ltd. romanized | Ren Fu Pu Ke Pharma (Wuhan) Co., Ltd. romanized | 国药准字H20264113 | 2026/04/21 | 0.25μg | Generic approved under the new chemical-drug registration classification | CDE |
| Ren Fu Pu Ke Pharma (Wuhan) Co., Ltd. romanized | Ren Fu Pu Ke Pharma (Wuhan) Co., Ltd. romanized | 国药准字H20264114 | 2026/04/21 | 0.5μg | Generic approved under the new chemical-drug registration classification | CDE |
| Guangzhou Bai Yun Shan Xing Qun (Pharma) Co., Ltd. romanized | Guangzhou Bai Yun Shan Xing Qun (Pharma) Co., Ltd. romanized | 国药准字H20020501 | 2026/02/03 | 0.25μg | Drug that passed quality-and-efficacy consistency evaluation | CDE |
| Guangzhou Bai Yun Shan Xing Qun (Pharma) Co., Ltd. romanized | Guangzhou Bai Yun Shan Xing Qun (Pharma) Co., Ltd. romanized | 国药准字H20051861 | 2026/02/03 | 0.5μg | Drug that passed quality-and-efficacy consistency evaluation | CDE |
| Da Lian Mei Chuang Pharma Co., Ltd. romanized | Da Lian Mei Chuang Pharma Co., Ltd. romanized | 国药准字H20263351 | 2026/02/02 | 0.25μg | Generic approved under the new chemical-drug registration classification | CDE |
| Da Lian Mei Chuang Pharma Co., Ltd. romanized | Da Lian Mei Chuang Pharma Co., Ltd. romanized | 国药准字H20263350 | 2026/02/02 | 0.5μg | Generic approved under the new chemical-drug registration classification | CDE |
| Dong Hai Pharmaceutical (Hebei) Co., Ltd. romanized | Dong Hai Pharmaceutical (Hebei) Co., Ltd. romanized | 国药准字H20263244 | 2026/01/27 | 0.25μg | Generic approved under the new chemical-drug registration classification | CDE |
| Beijing Wan Hui Shuang He Pharma Co., Ltd. romanized | Hua Run Shuang He Pharma Co., Ltd. romanized | 国药准字H20255672 | 2025/10/14 | 0.25μg | Generic approved under the new chemical-drug registration classification | CDE |
| Kunming Bei Ke Nuo Dun Pharmaceutical Co., Ltd. romanized | Kunming Bei Ke Nuo Dun Pharmaceutical Co., Ltd. romanized | 国药准字H20010320 | 2021/02/02 | 0.25μg | Drug that passed quality-and-efficacy consistency evaluation | CDE |
| Zheng Da Pharmaceutical (Qingdao) Co., Ltd. romanized | Zheng Da Pharmaceutical (Qingdao) Co., Ltd. romanized | 国药准字H19991114 | 2021/01/22 | 0.25μg | Drug that passed quality-and-efficacy consistency evaluation | CDE |
| LEO Pharma A/S | LEO Pharma A/S | H20130513 | 1998/07/09 | 0.25μg | Imported originator drug | CDE |
| Teva Pharmaceutical Industries Ltd. | Teva Pharmaceutical Industries Ltd. | H20171202;H20171203 | 1993/03/25 | 0.25μg | Imported originator drug | CDE |
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 24 distinct approval numbers and 14 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| Da Lian Mei Chuang Pharma Co., Ltd. romanized | 国药准字H20263350 | 0.5μg | Category B | XA11CCA017E002010101121 | NHSA |
| Ren Fu Pu Ke Pharma (Wuhan) Co., Ltd. romanized | 国药准字H20264113 | 0.25μg | Category B | XA11CCA017E002010109981 | NHSA |
| Hunan Yin Ze Hua Hao Bio Technology Co., Ltd. romanized | 国药准字H20264156 | 0.25μg | Category B | XA11CCA017E002010183641 | NHSA |
| An Rui Pharmaceutical (Hebei) Co., Ltd. romanized | 国药准字H20263244 | 0.25μg | Category B | XA11CCA017E002010184599 | NHSA |
| Da Lian Mei Chuang Pharma Co., Ltd. romanized | 国药准字H20263350 | 0.5μg | Category B | XA11CCA017E002010201121 | NHSA |
| Hunan Yin Ze Hua Hao Bio Technology Co., Ltd. romanized | 国药准字H20264156 | 0.25μg | Category B | XA11CCA017E002010283641 | NHSA |
| An Rui Pharmaceutical (Hebei) Co., Ltd. romanized | 国药准字H20263244 | 0.25μg | Category B | XA11CCA017E002010284599 | NHSA |
| Da Lian Mei Chuang Pharma Co., Ltd. romanized | 国药准字H20263350 | 0.5μg | Category B | XA11CCA017E002010301121 | NHSA |
| Hunan Yin Ze Hua Hao Bio Technology Co., Ltd. romanized | 国药准字H20264156 | 0.25μg | Category B | XA11CCA017E002010383641 | NHSA |
| An Rui Pharmaceutical (Hebei) Co., Ltd. romanized | 国药准字H20263244 | 0.25μg | Category B | XA11CCA017E002010384599 | NHSA |
| An Rui Pharmaceutical (Hebei) Co., Ltd. romanized | 国药准字H20263244 | 0.25μg | Category B | XA11CCA017E002010484599 | NHSA |
| Da Lian Mei Chuang Pharma Co., Ltd. romanized | 国药准字H20263351 | 0.25μg | Category B | XA11CCA017E002020101121 | NHSA |
| Ren Fu Pu Ke Pharma (Wuhan) Co., Ltd. romanized | 国药准字H20264114 | 0.5μg | Category B | XA11CCA017E002020109981 | NHSA |
| Hunan Yin Ze Hua Hao Bio Technology Co., Ltd. romanized | 国药准字H20264157 | 0.5μg | Category B | XA11CCA017E002020183641 | NHSA |
| Da Lian Mei Chuang Pharma Co., Ltd. romanized | 国药准字H20263351 | 0.25μg | Category B | XA11CCA017E002020201121 | NHSA |
| Hunan Yin Ze Hua Hao Bio Technology Co., Ltd. romanized | 国药准字H20264157 | 0.5μg | Category B | XA11CCA017E002020283641 | NHSA |
| Da Lian Mei Chuang Pharma Co., Ltd. romanized | 国药准字H20263351 | 0.25μg | Category B | XA11CCA017E002020301121 | NHSA |
| Hunan Yin Ze Hua Hao Bio Technology Co., Ltd. romanized | 国药准字H20264157 | 0.5μg | Category B | XA11CCA017E002020383641 | NHSA |
| Hua Run Shuang He Pharma Co., Ltd. romanized | 国药准字H20074109 | 0.25μg | Category B | XA11CCA017E002010100143 | NHSA |
| Beijing Wan Hui Shuang He Pharma Co., Ltd. romanized | 国药准字H20255672 | 0.25μg | Category B | XA11CCA017E002010100176 | NHSA |
| Guangzhou Bai Yun Shan Xing Qun (Pharma) Co., Ltd. romanized | 国药准字H20020501 | 0.25μg | Category B | XA11CCA017E002010100423 | NHSA |
| Shanghai Xin Yi Wan Xiang Pharma Co., Ltd. romanized | 国药准字H20010618 | 0.25μg | Category B | XA11CCA017E002010100805 | NHSA |
| Nan Tong Hua Shan Pharma Co., Ltd. romanized | 国药准字H20000065 | 0.25μg | Category B | XA11CCA017E002010101620 | NHSA |
| Qingdao Guo Xin Pharmaceutical Co., Ltd. romanized | 国药准字H19991114 | 0.25μg | Category B | XA11CCA017E002010104036 | NHSA |
| Teva Pharmaceutical Industries Ltd. | 国药准字J20171090 | 0.25μg | Category B | XA11CCA017E002010105580 | NHSA |
| Teva Pharmaceutical Industries Ltd. | H20171202 | 0.25μg | Category B | XA11CCA017E002010178914 | NHSA |
| CHEPLAPHARM Arzneimittel GmbH | 国药准字HJ20130513 | 0.25μg | Category B | XA11CCA017E002010179051 | NHSA |
| Hua Run Shuang He Pharma Co., Ltd. romanized | 国药准字H20074109 | 0.25μg | Category B | XA11CCA017E002010200143 | NHSA |
| Beijing Wan Hui Shuang He Pharma Co., Ltd. romanized | 国药准字H20255672 | 0.25μg | Category B | XA11CCA017E002010200176 | NHSA |
| Guangzhou Bai Yun Shan Xing Qun (Pharma) Co., Ltd. romanized | 国药准字H20020501 | 0.25μg | Category B | XA11CCA017E002010200423 | NHSA |
| Shanghai Xin Yi Wan Xiang Pharma Co., Ltd. romanized | 国药准字H20010618 | 0.25μg | Category B | XA11CCA017E002010200805 | NHSA |
| Nan Tong Hua Shan Pharma Co., Ltd. romanized | 国药准字H20000065 | 0.25μg | Category B | XA11CCA017E002010201620 | NHSA |
| Qingdao Guo Xin Pharmaceutical Co., Ltd. romanized | 国药准字H19991114 | 0.25μg | Category B | XA11CCA017E002010204036 | NHSA |
| Teva Pharmaceutical Industries Ltd. | 国药准字J20171090 | 0.25μg | Category B | XA11CCA017E002010205580 | NHSA |
| Teva Pharmaceutical Industries Ltd. | H20171202 | 0.25μg | Category B | XA11CCA017E002010278914 | NHSA |
| Nan Tong Hua Shan Pharma Co., Ltd. romanized | 国药准字H20000065 | 0.25μg | Category B | XA11CCA017E002010301620 | NHSA |
| Qingdao Guo Xin Pharmaceutical Co., Ltd. romanized | 国药准字H19991114 | 0.25μg | Category B | XA11CCA017E002010304036 | NHSA |
| Kunming Bei Ke Nuo Dun Pharmaceutical Co., Ltd. romanized | 国药准字H20010320 | 0.25μg | Category B | XA11CCA017E002010305580 | NHSA |
| Qingdao Guo Xin Pharmaceutical Co., Ltd. romanized | 国药准字H19991114 | 0.25μg | Category B | XA11CCA017E002010404036 | NHSA |
| Kunming Bei Ke Nuo Dun Pharmaceutical Co., Ltd. romanized | 国药准字H20010320 | 0.25μg | Category B | XA11CCA017E002010405580 | NHSA |
| Qingdao Guo Xin Pharmaceutical Co., Ltd. romanized | 国药准字H19991114 | 0.25μg | Category B | XA11CCA017E002010504036 | NHSA |
| Guangzhou Bai Yun Shan Xing Qun (Pharma) Co., Ltd. romanized | 国药准字H20051861 | 0.5μg | Category B | XA11CCA017E002020100423 | NHSA |
| Shanghai Xin Yi Wan Xiang Pharma Co., Ltd. romanized | 国药准字H20010619 | 0.5μg | Category B | XA11CCA017E002020100805 | NHSA |
| Nan Tong Hua Shan Pharma Co., Ltd. romanized | 国药准字H20000066 | 0.5μg | Category B | XA11CCA017E002020101620 | NHSA |
| Teva Pharmaceutical Industries Ltd. | 国药准字J20171093 | 1μg | Category B | XA11CCA017E002020105580 | NHSA |
| Teva Pharmaceutical Industries Ltd. | H20171205 | 1μg | Category B | XA11CCA017E002020178914 | NHSA |
| CHEPLAPHARM Arzneimittel GmbH | 国药准字HJ20130514 | 1μg | Category B | XA11CCA017E002020179051 | NHSA |
| Guangzhou Bai Yun Shan Xing Qun (Pharma) Co., Ltd. romanized | 国药准字H20051861 | 0.5μg | Category B | XA11CCA017E002020200423 | NHSA |
| Shanghai Xin Yi Wan Xiang Pharma Co., Ltd. romanized | 国药准字H20010619 | 0.5μg | Category B | XA11CCA017E002020200805 | NHSA |
| Da Lian Ao Sen Pharmaceutical Co., Ltd. romanized | 国药准字H20067903 | 0.25μg | Category B | XA11CCA017E002020201137 | NHSA |
| Nan Tong Hua Shan Pharma Co., Ltd. romanized | 国药准字H20000066 | 0.5μg | Category B | XA11CCA017E002020201620 | NHSA |
| Da Lian Ao Sen Pharmaceutical Co., Ltd. romanized | 国药准字H20067903 | 0.25μg | Category B | XA11CCA017E002020301137 | NHSA |
| Nan Tong Hua Shan Pharma Co., Ltd. romanized | 国药准字H20000066 | 0.5μg | Category B | XA11CCA017E002020301620 | NHSA |
| Da Lian Ao Sen Pharmaceutical Co., Ltd. romanized | 国药准字H20067903 | 0.25μg | Category B | XA11CCA017E002020401137 | NHSA |
| Da Lian Ao Sen Pharmaceutical Co., Ltd. romanized | 国药准字H20067903 | 0.25μg | Category B | XA11CCA017E002020501137 | NHSA |
| Da Lian Ao Sen Pharmaceutical Co., Ltd. romanized | 国药准字H20067903 | 0.25μg | Category B | XA11CCA017E002020601137 | NHSA |
| Da Lian Ao Sen Pharmaceutical Co., Ltd. romanized | 国药准字H20067903 | 0.25μg | Category B | XA11CCA017E002020701137 | NHSA |
| Da Lian Ao Sen Pharmaceutical Co., Ltd. romanized | 国药准字H20067903 | 0.25μg | Category B | XA11CCA017E002020801137 | NHSA |
| Da Lian Ao Sen Pharmaceutical Co., Ltd. romanized | 国药准字H20067903 | 0.25μg | Category B | XA11CCA017E002020901137 | NHSA |
| Da Lian Ao Sen Pharmaceutical Co., Ltd. romanized | 国药准字H20067903 | 0.25μg | Category B | XA11CCA017E002021001137 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 9 filings and 7 distinct first applicants.
Generic 6 · Supplement 3
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| Liaoning Xin Shan Yuan Pharma Co., Ltd. romanized; Da Lian Mei Chuang Pharma Co., Ltd. romanized | CYHS2602098 | Generic | 2026/08/24 | Not stated by source | CDE |
| Liaoning Xin Shan Yuan Pharma Co., Ltd. romanized; Da Lian Mei Chuang Pharma Co., Ltd. romanized | CYHS2602097 | Generic | 2026/08/24 | Not stated by source | CDE |
| Da Lian Ao Sen Pharmaceutical Co., Ltd. romanized | CYHB2650174 | Supplement | 2026/08/20 | Not stated by source | CDE |
| Qingdao Shuang Jing Pharma Co., Ltd. romanized | CYHS2601939 | Generic | 2026/08/10 | Not stated by source | CDE |
| Shandong Jian Dao Pharmaceutical Co., Ltd. romanized | CYHS2600677 | Generic | 2026/03/19 | Not stated by source | CDE |
| Shanghai Xin Yi Wan Xiang Pharma Co., Ltd. romanized | CYHB2650008 | Supplement | 2026/01/08 | Not stated by source | CDE |
| Shijiazhuang Ke Ren Pharmaceuticals Technology Co., Ltd. romanized | CYHS2503283 | Generic | 2025/09/05 | Not stated by source | CDE |
| Shijiazhuang Ke Ren Pharmaceuticals Technology Co., Ltd. romanized | CYHS2503282 | Generic | 2025/09/05 | Not stated by source | CDE |
| Qingdao Guo Xin Pharmaceutical Co., Ltd. romanized | CYHB2501261 | Supplement | 2025/06/27 | Not stated by source | CDE |
New generic filings in 2026
Loaded records: 4 filings and 3 distinct first applicants.
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| Liaoning Xin Shan Yuan Pharma Co., Ltd. romanized; Da Lian Mei Chuang Pharma Co., Ltd. romanized | CYHS2602098 | Generic | 2026/08/24 | Not stated by source | CDE |
| Liaoning Xin Shan Yuan Pharma Co., Ltd. romanized; Da Lian Mei Chuang Pharma Co., Ltd. romanized | CYHS2602097 | Generic | 2026/08/24 | Not stated by source | CDE |
| Qingdao Shuang Jing Pharma Co., Ltd. romanized | CYHS2601939 | Generic | 2026/08/10 | Not stated by source | CDE |
| Shandong Jian Dao Pharmaceutical Co., Ltd. romanized | CYHS2600677 | Generic | 2026/03/19 | Not stated by source | CDE |
API registrations
Non-component matches: 9 companies with A status and 4 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| 阿法骨化醇 · No verified English name | Hebei Chuang Jian Pharma Co., Ltd. romanized | Y20240001503 | I | Exact ingredient | 2025/07/03 | CDE |
| 阿法骨化醇 · No verified English name | Formosa Laboratories, Inc. | Y20230000706 | A | Exact ingredient | 2026/05/20 | CDE |
| 阿法骨化醇 · No verified English name | Shanghai Xin Yi Wan Xiang Pharma Co., Ltd. romanized | Y20230000101 | A | Exact ingredient | 2024/09/24 | CDE |
| 阿法骨化醇 · No verified English name | Wuxi Fu Qi Pharmaceutical Co., Ltd. romanized | Y20210000218 | I | Exact ingredient | 2021/04/13 | CDE |
| 阿法骨化醇 · No verified English name | YaoPharma Co., Ltd. | Y20190009700 | A | Exact ingredient | — | CDE |
| 阿法骨化醇 · No verified English name | Qingdao Guo Xin Pharmaceutical Co., Ltd. romanized | Y20190009399 | A | Exact ingredient | 2025/01/15 | CDE |
| 阿法骨化醇 · No verified English name | Hua Run Shuang He Pharma Co., Ltd. romanized | Y20190006915 | A | Exact ingredient | 2023/03/24 | CDE |
| 阿法骨化醇 · No verified English name | Zhejiang Apeloa Kangyu Pharmaceutical Co., Ltd. | Y20190002277 | A | Exact ingredient | 2024/12/07 | CDE |
| 阿法骨化醇 · No verified English name | YaoPharma Co., Ltd. | Y20180001705 | A | Exact ingredient | 2025/09/27 | CDE |
| 阿法骨化醇 · No verified English name | Zheng Da Pharmaceutical (Qingdao) Co., Ltd. romanized | Y20180000360 | I | Exact ingredient | 2018/08/27 | CDE |
| 阿法骨化醇 · No verified English name | Nanjing Hai Rong Pharmaceutical Co., Ltd. romanized | Y20180000715 | A | Exact ingredient | 2025/03/23 | CDE |
| 阿法骨化醇 · No verified English name | Shanghai Xin Yi Wan Xiang Pharma Co., Ltd. romanized | Y20170001885 | I | Exact ingredient | — | CDE |
| 阿法骨化醇 · No verified English name | Tai Yao Chemical Co., Ltd. romanized | Y20170000266 | A | Exact ingredient | 2022/09/05 | CDE |
| 阿法骨化醇 · No verified English name | CARBOGEN AMCIS B.V. | Y20170000231 | A | Exact ingredient | 2024/11/20 | CDE |
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/13 06:39. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
This source was last successfully updated at 2026/11/12 18:32; current coverage may be incomplete.
-
2026/08/24Accepted
Liaoning Xin Shan Yuan Pharma Co., Ltd. romanized; Da Lian Mei Chuang Pharma Co., Ltd. romanized
CYHS2602098
Fact date: 2026/08/24 · Site observation date: 2026/10/22
View source ↗ -
2026/08/24Accepted
Liaoning Xin Shan Yuan Pharma Co., Ltd. romanized; Da Lian Mei Chuang Pharma Co., Ltd. romanized
CYHS2602097
Fact date: 2026/08/24 · Site observation date: 2026/10/22
View source ↗ -
2026/08/20Accepted
Da Lian Ao Sen Pharmaceutical Co., Ltd. romanized
CYHB2650174
Fact date: 2026/08/20 · Site observation date: 2026/10/22
View source ↗
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/13 06:42
- Chemical-drug catalogue
- Last successful update: 2026/11/13 06:39
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/13 06:41
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/12 18:32 · Current coverage may be incomplete
First index-page publication dates: 2026-10-29 to 2026-11-13; 2 pages pending. Covers loaded notices only, not a complete historical approval database.
- Drug Clinical Trial Registry and Information Disclosure Platform
- Last successful update: 2026/11/13 08:09 · Current coverage may be incomplete
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 7/30; discovered pending details: 13. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to Alfacalcidol Soft Capsules
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Sign in to subscribeYearly
US$1,920
Billed every year
US$160 per month
Sign in to subscribeNeed more than 10 followed products or more than 5 recipients? Contact us.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
Billed by Creem, our merchant of record · Terms · Refund policy